CTMX - サイトメックス・セラピュ―ティクス (CytomX Therapeutics Inc.) サイトメックス・セラピュ―ティクス

 CTMXのチャート


 CTMXの企業情報

symbol CTMx
会社名 CytomX Therapeutics Inc (サイトメックス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 シートムエックス・セラピューティクス(CytomX Therapeutics Inc.)は臨床段階の腫瘍学に従事するバイオ医薬品会社である。同社はProbodyテクノロジープラットフォームを使用して、臨床的に検証された標的に対する癌免疫療法を創出して薬物標的に対する癌治療法を開発する。パイプラインはプロボディーガン免疫療法、プロボディー薬物コンジュゲート、T細胞関与プロボディー二重特異性、ProCAR-NK細胞療法の各種治療法の開発に焦点を当てる。同社の製品候補はCX-072、CX-2009、CX-2029、細胞傷害性Tリンパ球関連タンパク質4(CTLA-4)、CX-188等がある。Probodyプラットフォームは、モノクローナル抗体に基づく治療を可能にするために、腫瘍組織中の活性プロテアーゼを利用する。研究的Probody治療はCX-072指向のプログラム・デスリガンド1等の免疫腫瘍学における臨床的有効な癌標的に対処する。   サイトメックス・セラピュ―ティクスは米国のバイオ医薬品企業。主に「Probody」技術プラットフォ―ムに基づく抗体治療に焦点を当て、がん免疫治療の研究開発に従事する。同技術は、がん細胞の特殊な環境において抗体の働きを強め、同時に健康な細胞内では抗がん剤作用を押さえることを目標にする。「PD-L1」抗体薬の臨床試験を行う。本社はサンフランシスコ。   CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
本社所在地 151 Oyster Point Boulevard Suite 400 South San Francisco CA 94080 USA
代表者氏名 Hoyoung Huh 湖寧
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-515-3185
設立年月日 40422
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数
url www.cytomx.com
nasdaq_url https://www.nasdaq.com/symbol/ctmx
adr_tso
EBITDA EBITDA(百万ドル) -39.47600
終値(lastsale) 16.47
時価総額(marketcap) 740552007.24
時価総額 時価総額(百万ドル) 754.94040
売上高 売上高(百万ドル) 86.73900
企業価値(EV) 企業価値(EV)(百万ドル) 419.79440
当期純利益 当期純利益(百万ドル) -64.26600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CytomX Therapeutics Inc revenues increased 74% to $35.5M. Net loss decreased 14% to $28.9M. Revenues reflect Revenues increase of 83% to $35.5M. Lower net loss reflects Interest income increase from $442K to $2.9M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.91 to -$0.75.

 CTMXのテクニカル分析


 CTMXのニュース

   Edited Transcript of CTMX earnings conference call or presentation 6-Aug-20 9:30pm GMT  2020/08/07 21:29:46 Yahoo Finance
Q2 2020 CytomX Therapeutics Inc Earnings Call
   Shareholder Alert: Robbins LLP Reminds Investors CytomX Therapeutics, Inc. (CTMX) Sued for Misleading Shareholders  2020/07/01 22:32:00 Business Wire
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $CTMX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 17, 2018 and May 13, 2020. CytomX is an oncology-focused biopharmaceutical company in the United States. CytomX's lead product candidates in the clinical stage include CX-072 and CX-2009. If you suffered a loss
   Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX  2020/06/03 21:04:01 MarketScreener
NEW YORK, June 03, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. and certain of its officers. The class action,…
   Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?  2020/06/01 13:46:00 Zacks Investment Research
CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors  2020/05/27 23:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CTMX #classaction--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors
   Edited Transcript of CTMX earnings conference call or presentation 6-Aug-20 9:30pm GMT  2020/08/07 21:29:46 Yahoo Finance
Q2 2020 CytomX Therapeutics Inc Earnings Call
   Shareholder Alert: Robbins LLP Reminds Investors CytomX Therapeutics, Inc. (CTMX) Sued for Misleading Shareholders  2020/07/01 22:32:00 Business Wire
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $CTMX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 17, 2018 and May 13, 2020. CytomX is an oncology-focused biopharmaceutical company in the United States. CytomX's lead product candidates in the clinical stage include CX-072 and CX-2009. If you suffered a loss
   Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX  2020/06/03 21:04:01 MarketScreener
NEW YORK, June 03, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. and certain of its officers. The class action,…
   Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?  2020/06/01 13:46:00 Zacks Investment Research
CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors  2020/05/27 23:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CTMX #classaction--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors
   Edited Transcript of CTMX earnings conference call or presentation 6-Aug-20 9:30pm GMT  2020/08/07 21:29:46 Yahoo Finance
Q2 2020 CytomX Therapeutics Inc Earnings Call
   Shareholder Alert: Robbins LLP Reminds Investors CytomX Therapeutics, Inc. (CTMX) Sued for Misleading Shareholders  2020/07/01 22:32:00 Business Wire
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $CTMX #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 17, 2018 and May 13, 2020. CytomX is an oncology-focused biopharmaceutical company in the United States. CytomX's lead product candidates in the clinical stage include CX-072 and CX-2009. If you suffered a loss
   Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX  2020/06/03 21:04:01 MarketScreener
NEW YORK, June 03, 2020 -- Pomerantz LLP announces that a class action lawsuit has been filed against CytomX Therapeutics Inc. and certain of its officers. The class action,…
   Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?  2020/06/01 13:46:00 Zacks Investment Research
CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors  2020/05/27 23:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CTMX #classaction--Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of CytomX Therapeutics, Inc. (CTMX) Investors

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイトメックス・セラピュ―ティクス CTMX CytomX Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)